ARL16: A Potential Drug Target and Biomarker (G339231)

Target Name: ARL16

NCBI ID: G339231

ARL16

Other Name(s): ADP-ribosylation factor-like protein 16 | ARL16_HUMAN | ADP ribosylation factor like GTPase 16 | ADP-ribosylation factor-like 16

ARL16: A Potential Drug Target and Biomarker

ARL16 is a protein that belongs to the ARL16 family, which is known for its role in various cellular processes, including cell signaling, DNA replication, and protein synthesis. The ARL16 gene has been identified in various organisms, including humans, and its function is still poorly understood. However, recent studies have suggested that ARL16 may have potential as a drug target or biomarker. In this article, we will explore the potential of ARL16 as a drug target and biomarker, and discuss its potential clinical applications.

Potential Drug Target

ARL16 has been shown to play a role in various cellular processes that are crucial for human health. One of the key functions of ARL16 is its role in the regulation of DNA replication. ARL16 is a transcription factor that binds to the DNA template and helps to ensure the proper execution of DNA replication. In addition, ARL16 has also been shown to play a role in the regulation of cell signaling pathways, including the DNA replication and cell growth signaling pathways.

ARL16 has also been shown to interact with various drug targets, including the protein p53. The p53 protein is a well-known tumor suppressor protein that has been shown to play a critical role in the regulation of DNA replication and cell growth. By interacting with ARL16, the p53 protein may help to ensure that ARL16 functions properly and performs its critical functions in the regulation of cellular processes.

Potential Biomarker

ARL16 has also been shown to serve as a potential biomarker for various diseases, including cancer. One of the key reasons for its potential as a biomarker is its role in the regulation of cell signaling pathways, which are often disrupted in cancer cells. By studying the functions of ARL16, researchers may be able to identify new biomarkers for cancer, and develop new treatments.

In addition, ARL16 has also been shown to play a role in the regulation of cellular processes that are important for maintaining tissue homeostasis. This includes the regulation of the immune response, inflammation, and cellular signaling pathways. By studying the functions of ARL16, researchers may be able to identify new biomarkers for various diseases, including autoimmune diseases and inflammatory diseases.

Conclusion

In conclusion, ARL16 is a protein that has been shown to play a critical role in various cellular processes that are important for human health. Its potential as a drug target or biomarker makes it an attractive target for further research. Further studies are needed to fully understand the functions of ARL16 and its potential as a drug or biomarker. By studying the functions of ARL16, researchers may be able to develop new treatments and biomarkers for various diseases, including cancer and autoimmune diseases.

Protein Name: ADP Ribosylation Factor Like GTPase 16

Functions: May suppress the RNA sensing activity of RIGI in a GTP-dependent

The "ARL16 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ARL16 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets